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Abstract
Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons
containing the D1-like family of dopamine receptors and inputs of aversion coming from neurons containing the D2-like
family of dopamine receptors. Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two
pathways such that D1 reward seeking pathway dominates. Here, we provide an explanation at the cellular and biochemical
level how cocaine may achieve this. Exploring the effect of cocaine on dopamine D2 receptors function, we present
evidence of s1 receptor molecular and functional interaction with dopamine D2 receptors. Using biophysical, biochemical,
and cell biology approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with s1
receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers. We demonstrate that the
s1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to
s1 -D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum. In contrast, in
striatum from s1 knockout animals these complexes are not found and this inhibition is not seen. Taken together, these
data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor containing
neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor
containing neurons in the brain.
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Introduction
The striatum is the main input structure of the basal ganglia and
consists of subcortical structures involved in the processing of
information related with the performance and learning of complex
motor acts and motivational processes and is altered in conditions
such as Parkinson’s, Huntington’s and in drug addiction [1].
GABAergic striatal efferent neurons constitute more than 95% of
the striatal neuronal population [2]. There are two major subtypes
of GABAergic striatal efferent neurons: GABAergic dynorphiner-
gic neurons, which express the peptide dynorphin and dopamine
D1 receptors and GABAergic enkephalinergic neurons, which
express the peptide enkephalin and dopamine D2 receptors [3]. In
the case of drug addiction, and specifically cocaine, the
dopaminergic pathway plays a critical role in the pathology
[4,5], specifically, the two populations of D1 and D2 containing
neurons. These two pathways can control novelty seeking and
reward-dependent learning as well as having opposite effects on
motor activity [6]. Early studies performed in D1 receptor
knockout mice showed the importance of dopamine D1 receptor
in cocaine action as the activation of D1 receptors was an absolute
requirement for the induction of the cellular and behavioral
responses to cocaine [7]. In addition to opposing the locomotor
effects of D1, D2 containing neurons also serve to oppose drug
reinforcement [8]. In the context of cocaine it is known that the D2
is essential for cocaine’s effects [9] as D2 receptors are required to
enhance the rewarding properties of cocaine [10]. In D2 2/2
mutant animals the release of dopamine evoked by cocaine
injection is dramatically higher compared to WT animals, and an
intact D2-mediated signaling is required to elicit the rewarding and
reinforcing effects of cocaine [11]. At the mechanistic level it was
shown there is a switch from D2 to a D1 mediated increase on
GABAA-IPSC in cocaine treated rats [12], and in models of long-
term cocaine treatment it has been shown that D1 increases and
D2 levels decrease [13]. Finally, it has been shown that the
activation of postsynaptic D2 on striatopallidal neurons can
facilitate drug reinforcement via inhibition of these neurons [8].
All of these studies point to a balance between D1 and D2 in
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controlling the motivational processes and reinforcement in drugs
of abuse, and specifically cocaine.
The initial mechanistic steps of cocaine binding and its effects
on these two striatal populations of neurons (D1 and D2 receptor
containing neurons) are not well understood. What is known is
cocaine is able to exert part of its behavioral and cellular effect by
elevating dopamine levels in the striatum [14]. It achieves this by
binding to and inhibiting the presynaptic dopamine transporter
(DAT) [15]. Cocaine is a high-affinity inhibitor of DAT and upon
binding to DAT cocaine causes a rapid increase in extracellular
dopamine levels. Although DAT inhibition is required for
cocaine’s effects, it is not the only required mechanism of action
per the effects of D1 and D2 receptors discussed above. In fact,
Cocaine is able to modulate dopamine signaling, via both the D1
and D2 family of dopamine receptors, which when activated can
lead to stimulation or inhibition of signaling pathways. This
provokes the question, how does cocaine seemingly influence two
different receptor pathways? One potential answer lies in the fact
that cocaine does not seem to bind the dopamine receptors directly
but can bind to a receptor heteromer made up of the D1-like
receptor family member, D1 and the s1-receptor [16]. Through
this latter interaction, cocaine can potentiate D1 receptor-
mediated adenylyl cyclase activation, induce ERK1/2 phosphor-
ylation and counteract the MAPK activation induced by D1
receptor stimulation [16]. However, as discussed above, D2 also
plays a role in the early effects of cocaine. Here we explore the
initial molecular events after cocaine exposure on the dopamine
receptor D2 like family and test the hypothesis that s1 receptor
may provide the link between cocaine and the D1 and D2 receptor
signaling balance.
Materials and Methods
Ethics Statement
The study received the approval of the Catalan Ethical
Committee for Animal Use (CEAA/DMAH 4049 and 5664)
and all procedures were performed to minimize animal suffering.
Fusion Proteins and Expression Vectors
Sequences encoding amino acids residues 1–155 and 155–238
of YFP Venus protein, and amino acids residues 1–229 and 230–
311 of RLuc8 protein were subcloned in pcDNA3.1 vector to
obtain the YFP Venus (nVenus, cVenus) and RLuc8 (nRLuc8,
cRLuc8) hemi-truncated proteins expressed in pcDNA3.1 vector.
The human cDNA for the long isoform of dopamine D2 receptors
(D2 receptors), adenosine A2A or s1 receptors cloned in pcDNA3.1
were amplified without their stop codons using sense and antisense
primers harboring either unique EcoRI and BamHI sites (or EcoRI
and KpnI sites for s1 receptor). The fragments were then subcloned
to be in-frame with Rluc, EYFP or GFP2 into the EcoRI and
BamHI or KpnI restriction site of an Rluc-expressing vector (pRluc-
N1, PerkinElmer, Wellesley, MA), an EYFP expressing vector
(EYFP-N3; enhanced yellow variant of GFP; Clontech, Heidel-
berg, Germany) or an GFP2 expressing vector (GFP2-N2,
Clontech) respectively, to give the plasmids that express receptors
fused to either RLuc, YFP or GFP2 on the C-terminal end of the
receptor (D2-RLuc, D2-YFP, D2-GFP
2, s1-Rluc, s1-YFP, A2A-
RLuc or A2A-YFP receptors respectively). The human cDNAs for
D2 and s1 receptors cloned in pcDNA3.1 were amplified without
its stop codon using sense and antisense primers harboring unique
KpnI and EcoRI sites to clone D2 and s1 receptors in pcDNA3.1-
cVenus, pcDNA3.1-nVenus, pcDNA3.1-cRLuc8 or pcDNA3.1-
nRLuc8. The amplified fragments were subcloned to be in-frame
with the multiple cloning sites of the vectors to give the plasmids
that express D2 and s1 receptors fused to either nVenus, cVenus,
nRLuc8 or cRLuc8 on the C-terminal end of the receptor (D2-
cVenus, D2-nVenus, D2-cRLuc8, D2-nRLuc8, s1-nVenus, s1-
cVenus, s1-nRluc8 or s1-cRluc8, respectively). When analyzed by
confocal microscopy, it was observed that all fusion proteins
showed similar subcellular distribution than naı¨ve receptors (see
results and results not shown). Fusion of RLuc and YFP to D2 or
A2A receptors did not modify receptor function as previously
determined by cAMP assays [17].
Cell Culture and Chemical Reagents
HEK-293T cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 2 mM L-glutamine, 100 U/
ml penicillin/streptomycin, and 5% (v/v) heat inactivated Fetal
Bovine Serum (FBS) (all supplements were from Invitrogen,
Paisley, Scotland, UK). CHO cell lines were maintained in a-
MEM medium without nucleosides, containing 10% fetal calf
serum, 50 mg/mL penicillin, 50 mg/mL streptomycin, and 2 mM
L-glutamine (300 mg/mL). Cells were maintained at 37uC in an
atmosphere of 5% CO2, and were passaged when they were 80–
90% confluent, i.e. approximately twice a week. HEK-293T or
CHO cells were transiently transfected with the corresponding
cDNAs by PEI (PolyEthylenImine, Sigma, St. Louis, MO, USA)
method as previously described [18]or the corresponding siRNA
by lipofectamine (InvitrogenTM, Carlsbad, USA) method following
the instructions of the supplier. siRNA that targets both human
and rodent s1 RNA and a scrambled control siRNA were
purchased from Invitrogen (catalog HSS 145543). All ligands used
are diagrammed in Figure S1. Cocaine-HCl was purchased from
Spanish Agencia del Medicamento nu: 2003C00220. PD144418
and PRE were purchased from Tocris, Bristol, UK. Quinpirole
and raclopride were purchased from Sigma, St. Louis, MO, USA.
Immunocytochemistry
For immunocytochemistry, cells were fixed in 4% paraformal-
dehyde for 15 min and washed with PBS containing 20 mM
glycine (buffer A) to quench the aldehyde groups. Then, after
permeabilization with buffer A containing 0.2% Triton X-100 for
5 min, cells were treated with PBS containing 1% bovine serum
albumin. After 1 h at room temperature, cells were labeled with
the primary mouse monoclonal anti-Rluc receptor antibody (1/
200, Millipore, CA, USA) or mouse monoclonal anti-s1 receptor
antibody (1/200; Chemicon) for 1 h, washed, and stained with the
secondary Cy3 donkey anti-mouse antibody (1/200, Jackson
Immunoresearch Laboratories, West Grove, PA, USA). D2
receptors fused to YFP protein were detected by their fluorescence
properties. Samples were rinsed and observed in a Leica SP2
confocal microscope (Leica Microsystems, Mannheim, Germany).
BRET and BRET with BiFC Assays
HEK-293T cells growing in six-well plates were transiently co-
transfected with a constant amount of cDNA encoding for the
receptor fused to RLuc or nRLuc8 and cRLuc8 proteins and with
increasingly amounts of cDNA corresponding to the receptor
fused to YFP or nVenus and cVenus proteins (see figure legends).
To quantify receptor-YFP expression or receptor-reconstituted
YFP Venus expression, cells (20 mg protein) were distributed in 96-
well microplates (black plates with a transparent bottom) and
fluorescence was read in a Fluoro Star Optima Fluorimeter (BMG
Labtechnologies, Offenburg, Germany) equipped with a high-
energy xenon flash lamp, using a 10 nm bandwidth excitation
filter at 400 nm reading. Receptor-fluorescence expression was
determined as fluorescence of the sample minus the fluorescence of
cells expressing the BRET donor alone. For BRET or BRET with
Sigma-1 and Dopamine D2 Receptor Heteromers
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BiFC measurements, the equivalent of 20 mg of cell suspension
were distributed in 96-well microplates (Corning 3600, white
plates; Sigma) and 5 mM coelenterazine H (Molecular Probes,
Eugene, OR) was added. After 1 minute for BRET or after 5 min
for BRET with BiFC of adding coelenterazine H, the readings
were collected using a Mithras LB 940 that allows the integration
of the signals detected in the short-wavelength filter at 485 nm
(440–500 nm) and the long-wavelength filter at 530 nm (510–
590 nm). To quantify receptor-RLuc or receptor-reconstituted
RLuc8 expression luminescence readings were also performed
after 10 minutes of adding 5 mM coelenterazine H. Both
fluorescence and luminescence of each sample were measured
before every experiment to confirm similar donor expressions
(about 150,000 luminescent units) while monitoring the increase
acceptor expression (10,000–70,000 fluorescent units). The net
BRET is defined as [(long-wavelength emission)/(short-wave-
length emission)]-Cf where Cf corresponds to [(long-wavelength
emission)/(short-wavelength emission)] for the donor construct
expressed alone in the same experiment. BRET is expressed as
mili BRET units, mBU (net BRET61000).
SRET Assays
HEK-293T cells growing in six-well plates were transiently co-
transfected with constant amounts of cDNAs encoding for both
receptor fused to RLuc and GFP2 proteins and with increasingly
amounts of cDNA corresponding to the receptor fused to YFP
protein and SRET was determined as previously described using
a Mithras LB 40 [19].
Striatal Slices Preparation
Brains from WT littermates and s1 receptor KO CD1 albino
Swiss male mice (8 weeks old, 25 g of weight) were generously
provided by Laboratorios Esteve (Barcelona, Spain) [20]. Brains
were rapidly removed from animals and striatal slices were
obtained as previously indicated [16,21].
Coimmunoprecipitation
Striatal slices from WT littermates and s1 receptor KO mice
were treated with medium or with 150 mM cocaine for 30 min.
The striatal tissue was disrupted with a Polytron homogenizer in
50 mM Tris-HCl buffer, pH 7.4, containing a protease inhibitor
mixture (1/1000, Sigma). The cellular debris was removed by
centrifugation at 13,000 g for 5 min at 4uC, and membranes were
obtained by centrifugation at 105,000 g for 1 h at 4uC.
Membranes were solubilized in ice-cold immunoprecipitation
buffer (phosphate-buffered saline (PBS), pH 7.4, containing 1%
(v/v) Nonidet P-40) and incubated for 30 min on ice before
centrifugation at 105,000 g for 1 h at 4uC. The supernatant
(1 mg/ml of protein) was processed for immunoprecipitation as
described in the immunoprecipitation protocol using a Dyna-
beadsH Protein G kit (Invitrogen) using goat anti-D2 receptor
antibody (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA). As
negative control anti-FLAG antibody (1:1000, Sigma) was used.
Protein was quantified by the bicinchoninic acid method (Pierce)
using bovine serum albumin dilutions as standards. Immunopre-
cipitates were separated on a denaturing 10% SDS-polyacryl-
amide gel and transferred onto PVDF membranes. Membranes
were blocked for 90 min in 5% Bovine (1% fat) dry milk and PBS-
Tween 20 (0.05% V/V). The following primary antibodies were
incubated overnight at 4uC in 5% milk and PBS-Tween 20 (0.05%
V/V): mouse anti-D2 receptor antibody (1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA) or mouse anti-s1 receptor
antibody B-5 (sc-137075) (1:800, Santa Cruz Biotechnology, Santa
Cruz, CA) and, after washing three times for 10 min in PBS
Tween-20 (0.05% V/V), membranes were incubated with the
secondary antibody rabbit anti-mouse-HRP (1:20,000, Dako,
Glostrup, Denmark) for 1 h at room temperature in 5% milk
and PBS-Tween 20 (0.05% V/V). After three washes with PBS
Tween-20 (0.05% V/V) and a final wash with PBS, bands were
detected with the addition of SuperSignal West Pico Chemilumi-
nescent Substrate (Pierce) and visualized with a LAS-3000
(Fujifilm). Analysis of detected bands was performed by Image
Gauge software (version 4.0) and Multi Gauge software (version
3.0).
In Situ Proximity Ligation Assays (PLA)
Striatal slices from WT and s1 receptor KO mice treated or not
with 150 mM cocaine for 30 min, were mounted on slide glass and
heteromers were detected using the Duolink II in situ PLA
detection Kit (OLink; Bioscience, Uppsala, Sweden). Slices were
thawed at 4uC, washed in 50 mM Tris-HCl, 0.9% NaCl pH 7.8
buffer (TBS), permeabilized with TBS containing 0.01% Triton
X-100 for 10 min and successively washed with TBS. After 1 h
incubation at 37uC with the blocking solution in a pre-heated
humidity chamber, slices were incubated overnight in the antibody
diluent medium with a mixture of equal amounts of the primary
antibodies mouse anti-s1 receptor antibody B-5 (sc-137075, 1:500,
see above) and the guinea-pig anti-D2 receptor antibody (1:500
Sigma) which specificity for D2 receptors was previously demon-
strated [21]. Slices were washed as indicated by the supplier and
incubated for 2 h in a pre-heated humidity chamber at 37uC with
PLA probes detecting mouse or guinea pig antibodies, Duolink II
PLA probe anti-mouse plus and Duolink II PLA probe anti-guinea
minus (prepared following the instructions of the supplier) diluted
in the antibody diluent to a concentration of 1:5. After washing at
room temperature, slices were incubated in a pre-heated humidity
chamber for 30 min at 37uC, with the ligation solution (Duolink II
Ligation stock 1:5 and Duolink II Ligase 1:40). Detection of the
amplified probe was done with the Duolink II Detection Reagents
Red Kit. After exhaustively washing at room temperature as
indicated in the kit, slices were mounted using the mounting
medium with DAPI. The samples were observed in a Leica SP2
confocal microscope (Leica Microsystems, Mannheim, Germany).
Images were opened and processed with Image J confocal.
Immunohistochemistry
Striatal slices from WT and s1 receptor KO mice were thawed
at 4uC, washed in TBS, permeabilized with TBS containing 0.1%
Triton X-100 for 10 min and successively washed with TBS. Slices
were rocked in Blocking reagent 1% (Roche, Sant Cugat del
Valle´s, Spain) for 1 h at 37uC in a humidified atmosphere and
incubated overnight at 4uC in a humidified atmosphere with the
primary antibodies: mouse anti-s1 receptor antibody B-5 (sc-
137075, 1:100, see above) or the guinea-pig anti-D2 receptor
antibody (1:100 Frontier Institute, Ishikari, Hokkaido, Japan), in
0.1% TBS-Tween, 0.1% BSA-Acetylated (Aurion, Wageningen,
The Netherlands), 7% SND. Slices were washed in TBS-Tween
0.05% and left for 2 h at room temperature in a humidified
atmosphere with the corresponding secondary antibodies: goat
anti-mouse (1:200, Alexa Fluor 488, Invitrogen) and goat anti-
guinea pig (1:200, Alexa Fluor 488, Invitrogen) in the same
medium. Then, the slices were washed in TBS-Tween 0.05%,
followed by a single wash in TBS before mounting in Mowiol
medium (Calbiochem, Merck, Darmstadt, Germany), covered
with a glass and left to dry at 4uC for 24 h. The sections were
observed and imaged in a Leica SP2 confocal microscope.
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cAMP Determination
Non transfected or transiently transfected CHO cells (see figure
legends) were treated for 10 min with the indicated concentrations
of D2 receptor agonist quinpirole, 30 mM cocaine or 100 nM of
the s1 receptor agonist PRE-084 alone or in combination. cAMP
production was determined using [3H]cAMP kit (Amersham
Biosciences, Uppsala, Sweden) following the instructions from the
manufacturer.
ERK 1/2 Phosphorylation Assays
WT and KO ice striatal slices were treated for the indicated
time with the indicated concentrations of cocaine and/or D2
receptor ligands, frozen on dry ice and stored at 280uC. When
ERK1/2 phosphorylation assays were performed in cell cultures,
CHO cells (48 h after transfection) were cultured in serum-free
medium for 16 h before the addition of the indicated concentra-
tion of cocaine or/and D2 receptor ligands for the indicated time.
Both, cells and slices were lysed in ice-cold lysis buffer (50 mM
Tris-HCl pH 7.4, 50 mM NaF, 150 mM NaCl, 45 mM b-
glycerophosphate, 1% Triton X-100, 20 mM phenyl-arsine oxide,
0.4 mM NaVO4 and protease inhibitor cocktail) and ERK 1/2
phosphorylation was determined as indicated elsewhere [16,22].
CellKey Label-free Assays
The CellKey system provides a universal, label-free, cell-based
assay platform that uses cellular dielectric spectroscopy (CDS) to
measure endogenous and transfected receptor activation in real
time in live cells [23]. Changes in the complex impedance (DZ or
dZ) of a cell monolayer in response to receptor stimulation were
measured. Impedance (Z) is defined by the ratio of voltage to
current as described by Ohm’s law (Z = V/I). CHO cell clones
stably expressing D2 receptors were grown to confluence in
a CellKey Standard 96 well microplate that contains electrodes at
the bottom of each well. For untreated cells or for cells
preincubated (overnight at 37uC) with PTx (10 ng/ml), medium
was replaced by HBSS buffer (Gibco) supplemented with 20 mM
HEPES 30 minutes prior to running the cell equilibration
protocol. A baseline was recorded for 5 minutes and then cells
were treated with increasing concentrations of the D2 receptor
agonist quinpirole or cocaine alone or in combination and data
was acquired for the following 10 minutes. To calculate the
impedance, small voltages at 24 different measurement frequencies
were applied to treated or non-treated cells. At low frequencies,
extracellular currents (iec) that pass around individual cells in the
layer were induced. At high frequencies, transcellular currents (itc)
that penetrate the cellular membrane were induced and the ratio
of the applied voltage to the measured current for each well is the
impedance. The data shown refer to the maximum complex
impedance induced extracellular currents (Ziec) response to the
ligand addition.
Results
s1 Receptors form Heteromers with Dopamine D2
Receptors but not with the Other D2-like Receptor Family
Members
We first examined whether the receptors of the D2-like family
could directly interact with s1 receptors and thus be a target for
cocaine binding. To do this we used the Bioluminescence
Resonance Energy Transfer (BRET) technology in HEK-293T
cells expressing a constant amount of D2 (long isoform), D3 or D4
dopamine receptors fused to Renilla Luciferase (RLuc) and in-
creasing amounts of s1 receptors fused to Yellow Fluorescence
Protein (YFP). Clear BRET saturation curves were obtained in
cells expressing D2-RLuc receptors and increasing amounts of s1-
YFP receptors with a BRETmax of 5567 mBU and a BRET50 of
2866 (Fig. 1a). In contrast, in cells expressing D3-RLuc or D4-
RLuc and s1-YFP receptors a low and linear non-specific BRET
signal was obtained thus confirming the specificity of the
interaction between D2-RLuc and s1-YFP receptors (Fig. 1b).
As a further control, cells were cotransfected with s1-YFP
receptors and adenosine A2A-Rluc receptors and no specific
BRET signal was obtained (Fig. 1a). These results indicate that s1
receptors selectively interact with dopamine D2 receptors and not
with the other members of the D2-like receptor family.
The s1 receptors are predominantly found in the endoplasmic
reticulum membrane and the plasma membrane [24] with one
hypothesis that it may be acting as a chaperone protein [25]. The
expression of s1 and D2 receptors at the plasma membrane level
was explored by analyzing the co-localization of both receptors by
confocal microscopy. HEK-293T cells were used in the assays
since they constitutively express s1 receptors, but not DAT [16].
As expected, a punctate s1 receptor staining in naı¨ve (Fig. 1c left
panels, top images) or cocaine-treated (Fig. 1c right panels, top
images) HEK-293T cells was detected. After transfection of the
cDNA corresponding to D2 receptors, a co-localization of s1
receptor and D2 receptors was detected at the plasma membrane
level in cells not treated with cocaine (Fig. 1c left panels, bottom
images) or in cells treated with 30 mM cocaine for 30 min (Fig. 1c
right panels, bottom images).
Higher Order Complex Formation between s1 Receptors
and Dopamine D2 Receptors
Recent crystal structures have demonstrated that homodimers
of GPCRs are possible, a fact that has been confirmed for
dopamine D2 receptors [26–30]. Considering that s1 may act as
a chaperone like molecule we investigated the possible formation
of higher order receptor complexes between s1 and D2 receptor
homomers. To test this we first needed to know whether s1-
receptors could form dimers, something that had not been
reported. First, we tested if s1 receptors can form dimers by
BRET experiments in HEK-293T cells expressing a constant
amount of s1-RLuc receptors and increasing amounts of s1-YFP
receptors. A positive and saturable BRET signal was obtained with
a BRETmax of 165635 mBU and a BRET50 of 22612 (Fig. 2a)
indicating that s1-s1 homodimers can exist and demonstrating,
for the first time, the oligomerization of s1 receptors. Next, we
tested whether D2 receptor homomers could interact with s1-
receptors by a combined BRET and FRET assay termed
Sequential Resonance Energy Transfer (SRET) [19]. This assay
involves two sequential energy transfer events, one bioluminescent
energy transfer between Rluc and a blue shifted GFP2 and
a second fluorescent energy transfer event between excited GFP2
and YFP (see Fig. 2b top scheme). In HEK-293T cells expressing
a constant amount of D2-RLuc and D2-GFP
2 receptors and
increasing amounts of s1-YFP receptors, a net SRET saturation
curve was obtained with a SRETmax of 269633 SU and a SRET50
of 92624 (Fig. 2b). Cells expressing constant amounts of
adenosine A2A-RLuc and A2A-GFP
2 receptors and increasing
amounts of s1-YFP receptors provided very low and linear SRET,
according to the lack of interaction between A2A receptors and s1
receptors. These results demonstrate that s1 receptors are able to
form heteromers with D2-D2 receptor homomers. A net SRET
saturation curve was also obtained using HEK-293T cells
expressing constant amounts of s1-Rluc and D2-GFP
2 and
increasing amounts of s1-YFP (SRETmax: 14068 SU; SRET50:
963) but not when D2-RLuc and D2-GFP
2 receptors were
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replaced by A2A-RLuc and A2A-GFP
2 receptors (Fig. 2c). These
results demonstrate that D2 receptors are able to form heteromers
with s1-s1 receptor homomers. Finally, we tested for a higher
order interaction of receptor heteromers constituted by s1 and D2
receptor homomers (s1-s1-D2-D2). This was done using a modi-
fied BRET assay that involves a double complementation assay
[30]. A diagram showing the BRET with luminescence/fluores-
cence complementation approach (BRET with BiFC assay; see
Methods) is shown in Figure 2d (top panel). Briefly, one receptor
fused to the N-terminal fragment (nRluc8) and another receptor
fused to the C-terminal fragment (cRluc8) of the Rluc8 act as
BRET donor after Rluc8 reconstitution by a close receptor-
receptor interaction and one receptor fused to an YFP Venus N-
terminal fragment (nVenus) and another receptor fused to the YFP
Venus C-terminal fragment (cVenus), act as BRET acceptor after
YFP Venus reconstitution by a close receptor-receptor interaction.
Accordingly, cells were co-transfected with a constant amount of
the two cDNAs corresponding to D2-nRLuc8 and D2-cRLuc8
(equal amounts of the two cDNAs) and with a constant amount of
the two cDNAs corresponding to s1-nVenus and s1-cVenus
(equal amounts of the two cDNAs). Specific BRET would only be
possible if RLuc reconstituted by D2-nRLuc8-D2-cRLuc8 di-
merization is close enough to YFP Venus reconstituted by s1-
nVenus-s1-cVenus dimerization. Higher order heterotetramers
were in fact observed as evidenced by a positive BRET signal
(Fig. 2d). As negative controls, cells expressing only three fusion
proteins and the fourth receptor not fused provided neither
a significant fluorescent signal nor a positive BRET (Figure 2d).
Collectively these results indicate that s1-D2 receptor heteromers
seem to be constituted by the interaction of receptor homomers
and the minimal structural unit is the s1-s1-D2-D2 receptor
heterotetramer.
The Effect of s1 Receptor Ligands on s1-D2 Receptor
Heterotetramer
It is known that cocaine can bind to s1 [25,31,32]. We sought
to measure the effect of cocaine binding to s1 receptors on s1-D2
receptor heteromers using BRET. We performed BRET experi-
ments in HEK-293T cells expressing a constant amount of D2-
RLuc receptors and increasing amounts of s1-YFP receptors in
the presence or in the absence of cocaine. The BRET saturation
curve was reduced when cells were treated for 30 min with 30 mM
of cocaine (BRETmax: 3566 mBU; BRET50: 2668) indicating
that cocaine binding to s1 receptors induces structural changes in
the s1-D2 receptor heteromer. The cells treated (10 min) with the
s1 agonist PRE084 (100 nM; BRETmax: 4068 mBU; BRET50:
Figure 1. Molecular interaction between s1 receptors and D2 receptors in living cells. BRET saturation experiments were performed with
HEK-293T cells co-transfected with: (a) D2-RLuc cDNA (0.4 mg, squares) or adenosine A2A-RLuc cDNA as negative control (0.2 mg, triangles) and
increasing amounts of s1-YFP cDNA (0.1 to 1 mg cDNA), (b) D3-RLuc cDNA (0.5 mg, squares) or D4-RLuc cDNA (0.5 mg, triangles) and increasing
amounts of s1-YFP cDNA (0.1 to 1 mg cDNA). The relative amount of BRET acceptor is given as the ratio between the fluorescence of the acceptor
minus the fluorescence detected in cells only expressing the donor, and the luciferase activity of the donor (YFP/Rluc). BRET data are expressed as
means 6 S.D. of five to six different experiments grouped as a function of the amount of BRET acceptor. In (c) confocal microscopy images of HEK-
293T cells transfected with D2-YFP or s1-RLuc (top panels) or co-transfected with D2-YFP and s1-RLuc (bottom panels), treated (right images) or not
(left images) with 30 mM cocaine for 30 min. s1 receptors (red) were identified by immunocytochemistry and D2 receptors (green) were identified by
its own fluorescence. Co-localization is shown in yellow. Scale bar:10 mm.
doi:10.1371/journal.pone.0061245.g001
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3166) but not with the antagonist PD144418 (1 mM; BRETmax:
4863 mBU; BRET50: 2065) also showed a decrease in the BRET
saturation curves. Interestingly, the s1 antagonist PD144418 is
able to revert the effect induced by cocaine (BRETmax: 5269
mBU; BRET50: 3167 in the presence of cocaine and PD144418)
(Fig. 3a). To know if structural changes in s1-s1 receptor
homomers or in D2-D2 receptor homomers can account for the
ligand-induced effect on s1-D2 receptor heteromers, we per-
formed BRET experiments first in cells expressing s1-RLuc and
s1–YFP receptors as indicated in Fig. 2a. Cells were treated for
10 min with 100 nM of the agonist PRE084 or 1 mM of the
antagonist PD144418 or for 30 min with 30 mM of cocaine alone
Figure 2. Higher order complex formation between s1 receptors and dopamine D2 receptors in living cells. In (a) BRET saturation
experiments were performed with HEK-293T cells co-transfected with s1-RLuc cDNA (0.2 mg) and increasing amounts of s1-YFP cDNA (0.1 to 0.6 mg
cDNA). A schematic representation of a BRET process is shown at top in which the receptor fused to RLuc acts as donor and the receptor fused to YFP
acts as acceptor. In (b) and (c) SRET saturation experiments were performed with HEK-293T cells co-transfected with: (b) a constant amount of D2-
RLuc (0.6 mg) and D2-GFP2 (1 mg) receptor cDNA (squares) or A2A-RLuc (0.3 mg) and A2A-GFP2 (0.5 mg) receptor cDNA, as negative control (triangles),
and increasing amounts of s1-YFP receptor (0.2 to 1.5 mg cDNA), (c) a constant amount of s1-Rluc (0.3 mg) and D2-GFP2 (1 mg) (triangles) or A2-GFP2
(0.5 mM) as negative control (squares) receptor cDNA and increasing amounts of s1-YFP receptor cDNA (0.2 to 1.5 mg). The relative amount of
acceptor is given as the ratio between the fluorescence of the acceptor minus the fluorescence detected in cells only expressing the donor, and the
luciferase activity of the donor (YFP/Rluc). A schematic representation of a SRET process is shown at top images in which two sequential energy
transfer events between Rluc and GFP2 (BRET process) and between GFP2 and YFP (FRET process) occurs. In (d) BRET with luminescence/fluorescence
complementation approach was performed measuring BRET in cells co-transfected with 1 mg of the two cDNAs corresponding to D2-nRLuc8 and D2-
cRLuc8 and with 1.5 mg of the two cDNAs corresponding to s1-nVenus and s1-cVenus (5). As negative controls, cells transfected with the same
amount of cDNA corresponding to D2-nRLuc8, D2-cRLuc8, s1-nVenus and cVenus (1), D2-nRLuc8, D2-cRLuc8, s1-cVenus and nVenus (2), D2-nRLuc8,
s1-nVenus, s1-cVenus and cRLuc8 (3), or D2-cRLuc8, s1-nVenus, s1-cVenus and nRLuc8 (4) did not display any significant luminescence or positive
BRET. A schematic representation of a BRET with luminescence/fluorescence complementation approach is given at the top image in which one
receptor fused to the N-terminal fragment (nRluc8) and another receptor fused to the C-terminal fragment (cRluc8) of the Rluc8 act as BRET donor
after Rluc8 reconstitution by a close receptor-receptor interaction and one receptor fused to an YFP Venus N-terminal fragment (nVenus) and another
receptor fused to the YFP Venus C-terminal fragment (cVenus), act as BRET acceptor after YFP Venus reconstitution by a close receptor-receptor
interaction. BRET or SRET data are expressed as means6 S.D. of five to six different experiments grouped as a function of the amount of BRET or SRET
acceptor.
doi:10.1371/journal.pone.0061245.g002
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or with 1 mM PD144418. As shown in Fig. 3b, no significant
changes in BRETmax or BRET50 were observed. Then, changes in
the BRET saturation curve obtained in cells expressing a constant
amount of D2-RLuc receptors and increasing amounts of D2-YFP
receptors (BRETmax: 4463 mBU; BRET50: 1264) were analyzed.
The BRET saturation curve changed in cells treated for 10 min
with 100 nM of PRE084 (BRETmax: 2765 mBU; BRET50: 1164)
or 30 min with 30 mM of cocaine (BRETmax: 2962 mBU;
BRET50: 1965) but not in cells treated for 10 min with 1 mM of
PD144418 (BRETmax: 4463 mBU; BRET50: 963). Again the
antagonist, PD144418, was able to revert the effect induced by
cocaine (BRETmax: 4362 mBU; BRET50: 1663 in cells pre-
treated with PD144418 and cocaine) (Fig. 3c). These data suggest
structural changes in the complex brought about by binding of
either the s1 agonist PRE084 or cocaine. To test whether the
effect of PRE084 or cocaine on D2-D2 heteromers are due to the
presence of s1 receptors, assays were performed in cells whose s1
receptor expression was knocked-down using an RNAi approach
(Fig. 3d). When we transfected a specific small interfering RNA
(siRNA), a robust silencing of s1 receptor expression was obtained
(Fig. S2). The treatment with the specific siRNA completely
abolished the effect of cocaine or PRE084 on the BRET saturation
curve. The treatment with PD144418 or PD144418 and cocaine
had no effect on these knocked-down cells (Fig. 3d). These results
suggest that ligand binding to s1 receptors induces strong changes
in the structure of the D2-D2 receptor homomers in the s1-D2
receptor heteromers.
Cocaine Binding to s1 Receptors Modulates the D2
Receptor Signaling in Transfected Cells
The cocaine-induced modifications of the quaternary structure
of D2 receptor homodimers in the s1-D2 receptor heteromer
described above suggest that cocaine can modulate the function-
ality of D2 receptors. To study how cocaine affects D2 receptor-
mediated signaling, Chinese hamster ovary (CHO) cells were used
as they provided a lower baseline of signaling for which to detect
downstream changes and have been shown to constitutively
express s1 receptors but not DAT [16]. The effect of cocaine on
D2 receptor agonist-induced, G protein-mediated signaling was
measured using a label free assay that measures changes in cell
impedance in response to stimulation. In CHO cells stably
expressing D2 receptors, increasing cocaine concentrations (10 nM
to 100 mM) did not give any G protein-mediated signaling, neither
Gi/0, GS or Gq (Fig. 4a) as compared to known control receptors
(Fig. S3). The signaling obtained upon D2 receptor activation with
the agonist quinpirole (0.1 nM to 1 mM) showed a Gi profile
(increases in impedance) that was completely blocked when cells
were treated with the Gi specific pertussis toxin (PTx) (Fig. 4b). We
observed a small but significant decrease in the Gi activation
induced by quinpirole when cells where pre-treated for 1 h with
30 mM cocaine (Fig. 4c). These results indicate that cocaine by
itself is not able to induce a G protein-mediated signaling but can
partially inhibit the ability of D2 receptors to signal through Gi. A
downstream consequence of Gi mediated signaling is the ability to
decrease cAMP signaling. In addition to the label free experiments
above we determined the levels of cAMP in CHO cells stably
expressing D2 receptors using forskolin and then measured
whether cocaine was able to decrease the forskolin-induced cAMP
formation. We found cocaine alone could not decrease the levels of
cAMP after treatment with forskolin compared to the D2 agonist
quinpirole (Fig. 4d). However, cocaine significantly dampened the
quinpirole-induced decreases of forskolin-mediated increases in
cAMP levels (Fig. 4d). This effect was blocked when cells were
transfected with siRNA against the s1 receptor (Fig. 4d),
demonstrating that cocaine’s ability to counteract the action of
quinpirole was mediated by s1 receptors. Similar results were
obtained when instead of cocaine the s1 receptor agonist PRE084
was used (Fig. S4) reinforcing the concept that s1 receptor ligands
induce a significant decrease in the ability of D2 receptors to signal
through Gi.
Apart from G protein-mediated signaling, many GPCRs are
able to signal in a G protein-independent way [33–37]. ERK 1/2
phosphorylation is one of the MAPK pathways that has been
described to be activated in a G protein-independent and arrestin-
dependent mechanism [36]. Several reports have highlighted the
importance of ERK 1/2 activation in D2 receptors containing
neurons for the effects of cocaine [38–41]. We sought to
understand how cocaine might influence s1-D2 receptor hetero-
mer-mediated ERK 1/2 signaling. Varying concentrations of
cocaine and varying the time of treatment did not lead to any
significant change in ERK 1/2 phosphorylation in response to
cocaine in cells not expressing D2 receptors (Fig. S5). Importantly,
cocaine per se dose-dependently (Fig. S6a) and time-dependently
(Fig. S6b) activated ERK 1/2 phosphorylation in cells expressing
D2 receptors. This effect was mediated by s1 receptors since it was
strongly diminished in cells transfected with the s1 receptors
siRNA (Figs. S6a and S6b). The D2 receptor agonist quinpirole
was also dose-dependently (Fig. S6c) and time-dependently (Fig.
S6d) able to activate ERK 1/2 phosphorylation but, as expected,
this effect was not mediated by s1 receptors since it was not
diminished in cells transfected with the s1 receptors siRNA (Figs.
S6c and S6d). These results point out that s1 or D2 receptor
activation in the s1-D2 receptor heteromer induces ERK 1/2
phosphorylation. Thus, cocaine, like quinpirole, can act as an
agonist at the MAPK activation level for the heteromer.
A property of some receptor heteromers is the ability of the
antagonist of one receptor to block the function of the agonist of
the partner receptor, a property defined as cross-antagonism
[22,42]. In cells expressing D2 receptors we looked for cross-
antagonism among s1-D2 receptor heteromers. Indeed we found
the cocaine-induced ERK 1/2 phosphorylation was counteracted
not only by the s1 receptor antagonist PD144418 (1 mM) but also
by the D2 receptor antagonist raclopride (10 mM) (Fig. 5a).
Analogously, the D2 receptor agonist quinpirole-induced ERK 1/
2 phosphorylation was blocked by raclopride but also by
PD144418 (Fig. 5b). These data suggest that antagonist binding
leads to structural changes within the receptor heteromer that
block signaling through the partner receptor. By definition an
antagonist cannot signal on its own, therefore this cross-
antagonism can only derive from the direct protein-protein
interactions established between the receptors in the s1-D2
receptor heteromer. This hypothesis is further supported by the
fact that silencing cells of the s1 receptor led to a complete loss in
this cross-antagonism. That is, the effect of PD144418 on
quinpirole-induced ERK1/2 phosphorylation was not observed
when cells were transfected with the siRNA for s1 receptors
(Fig. 5b).
As mentioned above cocaine can inhibit DAT and increase the
dopamine concentration in the striatum; so, in the presence of
cocaine both receptors in the s1-D2 receptor heteromer could be
activated. Therefore we asked, what happens to ERK 1/2
phosphorylation after co-activation of both receptors? Surprising-
ly, a negative cross-talk was detected. When cells expressing D2
receptors were treated with both 1 mM quinpirole and 30 mM
cocaine there was a decrease in ERK 1/2 phosphorylation
compared to quinpirole alone (Fig. 5c). This difference was not
seen if the cells were depleted of s1 receptors via siRNA (Fig. 5c).
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s1-D2 Receptor Heteromers are Found in the Brain
Striatum
The BRET experiments and the signaling experiments are all
suggestive of functional complexes that can lead to changes in D2
receptor function. However, all of these experiments were
performed in transfected cells. To establish whether these
complexes and their functional implications can be seen in tissue
we obtained striatum from wild type (WT) and s1 knockout (KO)
mice. The striatum express D2 receptor containing neurons of the
indirect motor pathway and is one of the key areas of the brain
where cocaine imposes its effects. First we examined whether s1-
D2 receptor heteromers could be detected in native tissue. We
performed Western blot experiments and found the expression of
both receptors in the striatum of WT mice and the expression of
D2 receptors but not s1 receptors in the striatum of KO mice
(Fig. 6a). Next we performed co-immunoprecipitation experiments
and found the antibody against D2 receptor could indeed co-
precipitate D2 receptors and s1 receptor (Fig. 6a) in WT mice
striatum treated or not with 150 mM cocaine. This co-pre-
cipitation was not observed when tissue from s1 receptor KO
animals was used (Fig. 6a). Although supportive of the BRET
experiments above and highly suggestive of heteromers in
striatum, we wanted to ensure that these complexes were not an
artifact of the detergent solubilization. To test this we used the
recently developed proximity ligation assay on slices of striatum
from both WT and s1 KO mice [42]. Using immunohistochem-
istry, we first checked the expression of s1 receptors in WT
animals but not in KO animals (Fig. S7) and the expression of D2
receptors in both WT and KO animals (Fig. S8). Next we
performed the proximity ligation assay on striatal slices from WT
animals. The slices were treated or not with 150 mM cocaine and
as shown in Figure 6 (b and d) a red punctate fluorescent staining
was observed, indicating both receptors are indeed in a complex in
mice striatum in the presence or absence of cocaine. As a negative
control we repeated this with only one of the two primary
antibodies, and staining was not seen (Fig. S9). As expected, the
Figure 3. Effect of s1 receptor ligands on s1-D2 receptor heteromer. BRET was measured in HEK-293T cells cotransfected with: (a) D2–Rluc
cDNA (0.4 mg) and increasing amounts of s1-YFP receptor cDNA (0.1 to 1 mg), (b) s1–Rluc cDNA (0.2 mg) and increasing amounts of s1-YFP receptor
cDNA (0.1 to 1 mg), (c) D2–Rluc cDNA (0.4 mg) and increasing amounts of D2-YFP receptor cDNA (0.2 to 2 mg) or (d) siRNA corresponding to s1
receptor (see Methods), D2–Rluc cDNA (0.4 mg) and increasing amounts of D2-YFP receptor cDNA (0.2 to 2 mg), not treated (black), treated for 30 min
with 30 mM cocaine (red), treated for 10 min with 100 nM PRE084 (blue) or 1 mM PD144418 (green) or treated for 30 min with 30 mM cocaine and
1 mM PD144418 (orange). The relative amount of BRET acceptor is given as the ratio between the fluorescence of the acceptor minus the
fluorescence detected in cells only expressing the donor, and the luciferase activity of the donor (YFP/Rluc). BRET data are expressed as means 6 SD
of four to six different experiments grouped as a function of the amount of BRET acceptor.
doi:10.1371/journal.pone.0061245.g003
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red punctate fluorescent staining was not observed when the
experiments were performed with striatal slices from s1 KO mice
(Fig. 6c and e). These data further support the existence of s1-D2
receptor heteromers in the striatum.
Cocaine Binding to s1 Receptors Modulates the D2
Receptor Signaling in Mouse Brain Striatum
The above data provide strong evidence of s1-D2 receptor
heteromers in vivo but they do not say anything about the
function of these complexes. We decided to test whether the
negative cross-talk seen in signaling in transfected cells could also
be found in the striatum. Striatum slices from WT and KO mice
were tested for the effects of cocaine on ERK 1/2 phosphoryla-
tion. In co-transfected cells a strong and significant effect of
cocaine was observed at 15 mM (see Fig. 5), a striatal level of the
drug reached after pharmacologically significant doses of cocaine
[43]. To allow diffusion into the tissue a ten-fold higher cocaine
concentration, 150 mM, was then used to see clear effects in slices
of mouse striatum. Both the D2 receptor agonist quinpirole (1 mM)
and cocaine (150 mM) induced ERK 1/2 phosphorylation in
striatal slices from WT mice after 10 min activation (Fig. S10) or
after 30 min activation (Fig. 7a). More interestingly, in striatal
slices of WT mice, the co-activation with quinpirole and cocaine
Figure 4. Cocaine binding to s1 receptor modulates the Gi-dependent D2 receptor signaling in transfected cells. In (a to c) CellKey
label-free assays were performed in CHO cells stable expressing D2 receptors. In (a) cells were stimulated with buffer (B) or with increasing
concentrations of cocaine. In (b) cells were preincubated (black columns) or not (white columns) with PTx (10 ng/ml) overnight and stimulated with
buffer (B) or increasing concentrations of quinpirole. In (c) cells were stimulated with increasing concentrations of cocaine in the presence of 10 nM of
quinpirole. In (d) cAMP production was determined in CHO cells stable expressing D2 receptors not transfected (black columns) or transfected (white
columns) with siRNA corresponding to s1 receptor (6.25 mg of oligonucleotides) and stimulated with 5 mM forskolin in absence (100%) or presence of
1 mM quinpirole, 30 mM cocaine alone or in combination. Percent of cAMP produced respect to 5 mM forskolin treatment was represented. Results
are as mean 6 S.E.M from 4–8 independent experiments. Statistical significance was calculated by one way ANOVA followed by Bonferroni multiple
comparison test; in b **p,0.01 and ***p,0.005 compared with cells not transfected with siRNA, in c *p,0.05 compared with cells only treated with
quinpirole, in d &&p,0.01 compared to the corresponding quinpirole-treated cells and *p,0.05 and ***p,0.005 compared with forskolin-treated
cells (100%).
doi:10.1371/journal.pone.0061245.g004
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blocked ERK 1/2 phosphorylation (Figs. 7a and S10). Thus, the
negative cross-talk between s1 and D2 receptors on MAPK
signaling detected in cotransfected cells was also observed in
striatal samples from WT mice, meaning that the same bio-
chemical fingerprint seen in transfected cells was also found in WT
mice. When similar experiments were performed in striatal slices
from mice lacking the s1 receptors, cocaine was unable to induce
ERK 1/2 phosphorylation (Figs. 7a and S10) and quinpirole-
induced ERK 1/2 phosphorylation was not modified by cocaine
(Figs. 7a and S10). These results strongly support the existence of
functional s1-D2 receptor heteromers in the striatum and indicate
that all detected cocaine effects are dependent on s1 receptors
expression.
Discussion
The data presented in this paper lead to several major
conclusions on the role s1 receptors play in modulating D2
receptor upon cocaine exposure. First, D2 receptors can form
heteromers with s1 receptors, a result that is specific to D2
receptors as the other members of the D2-like family, D3 and D4
receptors, did not form heteromers. Second, these s1-D2 receptor
heteromers are found in mouse striatum and are functional. Third,
s1-D2 receptor heteromers consist of higher order oligomers with
a minimal structure of s1-s1-D2-D2 receptor heterotetramers.
Finally, cocaine, by binding to s1-D2 receptor heteromers, inhibits
downstream signaling in both cultured cells and in mouse striatum.
Cocaine intake elevates dopamine levels in the striatum,
particularly in its more ventral part, the nucleus accumbens,
which has been shown to be a preferential anatomical substrate for
reward [44,45]. Cocaine exploits the dopaminergic system to elicit
part of its behavioral and cellular effects [14]. Earlier studies have
suggested that the presynaptic dopamine transporter (DAT) is the
primary target for cocaine effects [46–49]. However, not all
cocaine effects are mediated by a dopamine increase derived by
the cocaine inhibition of DAT. Indeed, cocaine interacts with
many proteins, and it is now well established that cocaine interacts
with s1 receptors at physiologically relevant concentrations [50–
55]. In fact, reducing brain s1 receptor levels with antisense
oligonucleotides attenuates the convulsive and locomotor stimu-
lant actions of cocaine [56,57] and antagonists for s1 receptors
have also been shown to mitigate the actions of cocaine in animal
models [50,58]. s1 receptors are highly expressed in the brain
[24,59]. Within the caudate-putamen and nucleus accumbens (the
dorsal and ventral parts of the striatum, respectively), brain regions
that mediate the long-term effects of cocaine, it was demonstrated
that repeated cocaine administration induces up-regulation of s1
receptors, a process mediated by dopamine D1 receptors [60].
Indeed, we have demonstrated earlier the importance of the s1
and D1 receptor interaction on the initial events upon cocaine
exposure [16]. In addition, others have shown s1 can modulate
signaling of a different GPCR family [61]. Through s1-D1
receptor heteromers, cocaine robustly potentiated D1 receptor-
mediated adenylyl cyclase activation, providing a mechanism for
D1 receptor-mediated effects of cocaine [16]. In addition to DAT
and D1 receptors, our work here highlights the importance of s1
receptors. Our data suggest that it is s1 receptors that are able to
Figure 5. Cocaine binding to s1 receptor modulates the ERK 1/2
signaling in transfected cells. CHO cells were transfected with D2
receptor cDNA (1 mg, black bars) or cotransfected (white bars) with D2
receptor cDNA and s1 receptor siRNA (6.25 mg of oligonucleotides).
Cells were incubated for 30 min (a) or 10 min (b) with medium (basal)
or with 30 mM cocaine (a) or 1 mM quinpirole (b) in the absence or in
the presence of 10 mM raclopride or 100 nM PD144418. In (c) cells were
treated with medium (basal), 30 mM cocaine for 30 min, 1 mM
quinpirole for 10 min or 30 mM cocaine for 30 min and, during the
last 10 min, with 1 mM quinpirole. In all cases, ERK 1/2 phosphorylation
is represented as percentage over basal levels (100%). Results are mean
6 SEM of six to eight independent experiments performed in duplicate.
Bifactorial ANOVA showed a significant (**p,0.01 and ***P,0.005)
effect over basal.
doi:10.1371/journal.pone.0061245.g005
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Figure 6. Expression of s1-D2 receptor heteromers in the striatum. In (a) co-immunoprecipitation experiments are shown. Striatal slices from
WT and KO mice were untreated or treated with 150 mM cocaine for 30 min. From slices solubilized striatal membranes (top panel) and
immunoprecipitates with anti-D2 receptor antibody or anti-FLAG antibody as negative control (NC) (middle and bottom panels) were analyzed by
SDS-PAGE and immunoblotted using mouse anti-D2 receptor antibody or mouse anti-s1 receptor antibody. IP: immunoprecipitation; WB: western
blotting; MW, molecular mass. In (b to e) Proximity Ligation Assay (PLA) was performed as indicated in Materials and Methods, using WT (b and d) or
KO (c and e) mouse striatal slices not treated (b and c) or treated (d and e) with 150 mM cocaine for 30 min. s1-D2 receptor heteromers were
visualized as red spots around blue colored DAPI stained nucleus. Scale bar: 20 mm.
doi:10.1371/journal.pone.0061245.g006
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directly modulate the normally balanced D1 and D2 pathways via
receptor-receptor interactions.
The cocaine effect on s1-D2 receptor heteromer signaling is in
contrast with the cocaine effect on s1-D1 receptor heteromer
signaling described by Navarro et al [16]. In the last case, the D1
receptor-mediated activation of cAMP production was significant-
ly increased by cocaine binding to a s1 protomer in the s1-D1
receptor heteromers, resulting in a cocaine-induced increase in
cAMP production. The results here described and those described
by Navarro et al [16], point to the scenario that is shown in
Figure 7b, where cocaine selectively leads to increased dopamine-
induced signaling through the cAMP pathway in D1 receptor-
containing neurons and to depressed dopamine-induced inhibition
of cAMP formation in D2 receptor-containing neurons. Simulta-
neously, cocaine alters the levels of the initial ERK 1/2
phosphorylation signaling induced by dopamine in both D1
receptor and D2 receptor-containing neurons. These findings
suggest that cocaine exposure leads to a deregulation of a normally
balanced D1/D2 dopamine receptor signaling (Fig. 7b). The
balance of D1 and D2 inputs is designed to avoid addictive
behavior, thus its disruption would have long term consequences.
The data presented here support a key role of s1 receptors in
destabilizing this balance by increasing the D1 receptor-mediated
cAMP production and dampening the D2 receptor signaling in s1-
D2 receptor heteromers, pushing the balance of inputs towards the
D1 containing, pro-reward and motivating pathway. Our data is
supported by the results described by Durieux and colleagues
where they found that striatal D2R neurons can limit both
locomotion and drug reinforcement and are organized in specific
cell types [6,8]. Luo et al [9], have found in vivo evidence for the
existence of D1 and D2 receptor-mediated cellular effects of
cocaine (D1 receptor-mediated increase in Ca
2+ influx and D2
receptor-mediated decrease in Ca2+ influx, using in vivo optical
microprobe Ca2+ influx imaging), with significantly slower
dynamics of the effect mediated by D2 receptors. Taking into
account our findings, the observations of Luo et al could in fact be
linked with the signaling brake imposed by cocaine on the s1-D2
receptor heteromer. Further, Ferraro et al. have found cocaine
alone had no effect on striatal glutamate levels but when injected
with a D2 ligand there were significant changes [62]. Xu et al have
shown that a s1 receptor ligand can reverse the effects of cocaine
in rats strongly suggesting that blocking cocaine’s actions via s1
receptor in s1-D2 complexes could serve as an effective strategy to
blunt the cellular signaling effects of cocaine [63]. Finally, Hiranita
et al have shown that a combined strategy of blocking DAT and
s1 is effective at reducing cocaine self-administration. However, in
a follow up study this same group shows that after cocaine self-
administration s1 receptor effects seem to be independent of
dopamine pathways [54]. These are in line with our observations
that the initial effects of cocaine disrupt the D1/D2 pathways. In
summary, the results described here along with the highlighted
previous studies support a model where the initial exposure to
cocaine affects differently the direct (D1 containing) and indirect
(D2 containing) pathways via s1 receptor heteromers which may
significantly influence dopaminergic neurotransmission.
Supporting Information
Figure S1 Chemical structure of compounds used. a)
cocaine, b) s1 receptor agonist PRE084, c) s1 receptor antagonist
PD144418, d) D2 receptor agonist quinpirole, e) D2 receptor
antagonist raclopride.
(TIF)
Figure S2 Effect of s1 receptor siRNA transfection on s1
receptor expression. Membranes from non-transfected HEK-
293T cells (wt) or cells transfected with s1 receptor siRNA
(6.25 mg of oligonucleotides) or irrelevant oligonucleotides (oligo,
6.25 mg of oligonucleotides) were analyzed by SDS/PAGE and
immunoblotted with the anti-s1 receptor antibody. Values are
mean 6 SEM of three experiments. ***P,0.001 compared with
non-transfected cells (one-way ANOVA followed by Bonferroni
post hoc tests).
(TIF)
Figure S3 Control CellKey label-free assays. HEK-293T
cells were stably transfected with the Gs protein-coupled adenosine
A2A receptor (a), the Gi protein-coupled adenosine A1 receptor (b)
or untransfected (c) in 96 well Cell-Key plates. Impedance changes
were measured upon addition of 10 nM CGS 21680 (A2A receptor
agonist) in (a), 10 nM CPA (A1 receptor agonist) in (b) or 50 nM
thrombin (the agonist for the endogenous Gq protein-couples
thrombin receptors) in (c). Plot shapes are consistent with the
expected results for the respective G-proteins.
(TIF)
Figure S4 s1 receptor agonist modulates the D2 re-
ceptor-mediated cAMP decreases. cAMP production was
determined in CHO cells stable expressing D2 receptors not
transfected (black columns) or transfected (white columns) with
siRNA corresponding to s1 receptor (6.25 mg of oligonucleotides).
Cells were stimulated with 5 mM forskolin in absence (100%) or
presence of 1 mM quinpirole, 100 nM PRE084 alone or in
combination. Percent of cAMP produced respect to forskolin
treatment was represented. Results are as mean6 S.E.M from five
independent experiments. Statistical significance was calculated by
one way ANOVA followed by Bonferroni multiple comparison
test; ***p,0.005 compared with forskolin-treated cells (100%) and
&& p,0.01 compared with the corresponding only quinpirole-
treated cells.
(TIF)
Figure S5 Cocaine effect on ERK 1/2 phosphorylation
in cells not expressing D2 receptors. CHO cells were
incubated with increasing cocaine concentrations for 30 min (a) or
with 30 mM cocaine for increasing time periods (b). ERK1/2
phosphorylation is represented as percentage over basal levels
(100%, non-treated cells). Results are mean 6 SEM of three to
four independent experiments performed in duplicate.
Figure 7. Negative cross-talk between cocaine and the D2 receptor agonist quinpirole on ERK 1/2 phosphorylation in mice striatum.
In (a) WT (black bars) and s1 receptor KO (white bars) mouse striatal slices were treated with 1 mM quinpirole for 10 min, with 150 mM cocaine for
30 min or with cocaine for 30 min and, during the last 10 min, with quinpirole. Immunoreactive bands from six slices obtained from five WT or five
KO animals were quantified for each condition. Values represent mean 6 SEM of percentage of phosphorylation relative to basal levels found in
untreated slices. No significant differences were obtained between the basal levels of the WT and the s1 receptor KO mice. Bifactorial ANOVA showed
a significant (*p,0.05, **p,0.01, ***p,0.005) effect over basal. One-way ANOVA followed by Bonferroni post hoc tests showed a significant cocaine-
mediated counteraction of quinpirole (&p,0.05, &&p,0.01). In (b) a representative scheme summarizing the overall results is shown. Top images
represent D2 and D1 receptors signaling in the indirect and direct striatal pathway neurons after dopamine binding. Bottom images represent the
effect of cocaine increasing the dopamine by inhibiting dopamine transporters (DAT) and interacting with s1 receptors within s1-D2 and s1-D1
receptor heteromers, changing the dopamine receptor signaling.
doi:10.1371/journal.pone.0061245.g007
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(TIF)
Figure S6 Cocaine-induced s1-D2 receptor heteromer-
mediated ERK 1/2 phosphorylation in transfected cells.
CHO cells transfected with D2 receptor cDNA (1 mg, black bars)
or cotransfected (white bars) with D2 receptor cDNA and s1
receptor siRNA (6.25 mg of oligonucleotides) were incubated with
increasing cocaine concentrations for 30 min (a), with 30 mM
cocaine for increasing time periods (b), with increasing quinpirole
concentrations for 10 min (c) or with 1 mM quinpirole for
increasing time periods (d). ERK1/2 phosphorylation is repre-
sented as percentage over basal levels (100%). Results are mean 6
SEM of four to six independent experiments performed in
duplicate. In all samples in (c) and (d) and samples without siRNA
transfection in (a) and (b), Bifactorial ANOVA showed a significant
(p,0.01) effect of cocaine or quinpirole over basal, and Bonferroni
post hoc tests showed a significant counteraction of cocaine effect
by siRNA (*p,0.05, **p,0.01 and ***p,0.005 compared with
sample with the same treatment and with siRNA transfection).
(TIF)
Figure S7 Expression of s1 receptor in the striatum. WT
(a) or s1 receptor KO (b) mouse striatal slices were processed for
immunohistochemistry as indicated in Materials and Methods
using an anti-s1 antibody. Cell nuclei were stained with DAPI
(blue). Scale bar: 20 mm.
(TIF)
Figure S8 Expression of D2 receptor in the striatum.
WT (a) or s1 receptor KO (b) mouse striatal slices were
processed for immunohistochemistry as indicated in Materials and
Methods using an anti-D2 antibody (green). Scale bar: 20 mm.
(TIF)
Figure S9 Negative controls for in situ proximity
ligation assays. Negative controls for in situ proximity ligation
assays (see Materials and Methods) were performed in WT mouse
striatal slices incubated with only anti-s1 (a) or anti-D2 (b)
antibody as primary antibodies. Cell nuclei were stained with
DAPI (blue). Scale bar: 20 mm.
(TIF)
Figure S10 Negative cross-talk between cocaine and the
D2 receptor agonist quinpirole on ERK 1/2 phosphory-
lation in mouse striatum. WT (black bars) and s1 receptor
KO (white bars) mouse striatal slices were treated for 10 min with
1 mM quinpirole, with 150 mM cocaine or with both. Immuno-
reactive bands from six slices obtained from five WT or five KO
animals were quantified for each condition. Values represent
mean 6 SEM of percentage of phosphorylation relative to basal
levels found in untreated slices. No significant differences were
obtained between the basal levels of the wild-type and the KO
mice. Bifactorial ANOVA showed a significant (**p,0.01,
***p,0.005) effect over basal. One-way ANOVA followed by
Bonferroni post hoc tests showed a significant cocaine-mediated
counteraction of quinpirole (&&&P,0.005).
(TIF)
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